To discuss the management of latent autoimmune diabetes in youth (LADY) in two young women using oral semaglutide and basal insulin in a case series.
Approach:
Case 1: A 20-year-old woman with obesity (BMI: 31.8 kg/m2) and autoimmune diabetes was initially treated with metformin and basal insulin. She was later switched to oral semaglutide, achieving significant weight loss (−20 kg) and optimal glycemic control after 12 months.
Case 2: A 13-year-old girl diagnosed with autoimmune diabetes was initially on multiple daily insulin injections. After 15 months on oral semaglutide, she showed optimal glycemic control and increased C-peptide levels.
Key Findings:
Both patients exhibited partially preserved beta-cell function.
Oral semaglutide led to significant weight loss and improved glycemic control.
This is the first case series demonstrating the efficacy of oral semaglutide in treating LADY.
Interpretation:
The findings suggest that oral semaglutide can be an effective treatment option for young patients with LADY, potentially improving glycometabolic outcomes and aiding in weight management.
Limitations:
The case series involves only two patients, which limits the generalizability of the findings.
Long-term effects and safety of oral semaglutide in this population remain to be established.
Conclusion:
Oral semaglutide combined with basal insulin may provide effective management for LADY, with beneficial effects on weight and metabolic health.
